Immunohistochemical (IHC) testing of estrogen receptors (ER), progesterone receptors (PR), HER2 and Ki-67 on breast cancer samples is carried out in the majority of clinical departments to predict response to therapies and to determine prognosis. This evidence concerns the gene PGR and breast cancer.